Evidence map›Paper›PMID 26320177›Full record

ArticleOncotarget2015

WT1-mediated repression of the proapoptotic transcription factor ZNF224 is triggered by the BCR-ABL oncogene.

Giorgia Montano, Karina Vidovic, Chiara Palladino, Elena Cesaro, Gaetano Sodaro, Concetta Quintarelli, Biagio De Angelis, Santa Errichiello, Fabrizio Pane, Paola Izzo and 3 more

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Exploring the Leukemogenic Potential of GATA-1Antioxidants (Basel, Switzerland) · 2021
    Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. The Combination ofCancer control : journal of the Moffitt Cancer Center
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 2 countries.

Giorgia MontanoDepartment of Molecular Medicine and Medical Biotechnology University of Naples Federico II, Naples, Italy.
Karina VidovicDepartment of Haematology and Transfusion Medicine, BioMedical Center, Lund University, Lund, Sweden.
Chiara PalladinoDepartment of Molecular Medicine and Medical Biotechnology University of Naples Federico II, Naples, Italy.
Elena CesaroDepartment of Molecular Medicine and Medical Biotechnology University of Naples Federico II, Naples, Italy.
Gaetano SodaroDepartment of Molecular Medicine and Medical Biotechnology University of Naples Federico II, Naples, Italy.
Concetta QuintarelliDepartment of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
Biagio De AngelisDepartment of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
Santa ErrichielloDepartment of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
Fabrizio PaneDepartment of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
Paola IzzoDepartment of Molecular Medicine and Medical Biotechnology University of Naples Federico II, Naples, Italy.
Michela GrossoDepartment of Molecular Medicine and Medical Biotechnology University of Naples Federico II, Naples, Italy.
Urban GullbergDepartment of Haematology and Transfusion Medicine, BioMedical Center, Lund University, Lund, Sweden.
Paola CostanzoDepartment of Molecular Medicine and Medical Biotechnology University of Naples Federico II, Naples, Italy.
University of Naples Federico II · ITLund University · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Kruppel-like protein ZNF224 is a co-factor of the Wilms' tumor 1 protein, WT1. We have previously shown that ZNF224 exerts a specific proapoptotic role in chronic myelogenous leukemia (CML) K562 cells and contributes to cytosine arabinoside-induced apoptosis, by modulating WT1-dependent transcription of apoptotic genes. Here we demonstrate that ZNF224 gene expression is down-regulated both in BCR-ABL positive cell lines and in primary CML samples and is restored after imatinib and second generation tyrosine kinase inhibitors treatment. We also show that WT1, whose expression is positively regulated by BCR-ABL, represses transcription of the ZNF224 gene. Finally, we report that ZNF224 is significantly down-regulated in patients with BCR-ABL positive chronic phase-CML showing poor response or resistance to imatinib treatment as compared to high-responder patients. Taken as a whole, our data disclose a novel pathway activated by BCR-ABL that leads to inhibition of apoptosis through the ZNF224 repression. ZNF224 could thus represent a novel promising therapeutic target in CML.

Indexed as

ApoptosisBlotting, WesternCell Line, TumorDown-RegulationDrug Resistance, NeoplasmFusion Proteins, bcr-ablGene Expression Regulation, NeoplasticHEK293 CellsHumansImatinib MesylateK562 CellsLeukemia, Myelogenous, Chronic, BCR-ABL PositivePromoter Regions, GeneticProtein BindingProtein Kinase InhibitorsRepressor ProteinsFusion Proteins, bcr-ablImatinib MesylateProtein Kinase InhibitorsRepressor ProteinsWT1 protein, humanWT1 ProteinsZNF224 protein, humanBCR-ABLchronic myeloid leukemiatyrosine kinase inhibitorsWT1ZNF224

Identifiers

PMID26320177
PMCPMC4695056
OpenAlexW1871677735

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.